Publication | Closed Access

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages

ThrombosisMedicineHematologyAndexanet AlfaRivaroxaban-associated Intracranial HemorrhagesHemostasisBrain InjuryNeurologyCoagulopathyBleeding DisorderCerebral Blood FlowStrokeAnticoagulantAtherosclerosisNeurovascular DiseaseHealth Sciences